Evidence map›Paper›PMID 40510422›Full record

ReviewFrontiers in pharmacology2025

Targeting ferroptosis with natural products in stroke: therapeutic mechanisms and translational opportunities.

Yingyi Zheng, Xi Tan, Xiaojie Wang, Rui Mao, Jianwen Guo

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yingyi Zheng *The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xi Tan *The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiaojie WangThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Rui MaoThe Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Jianwen GuoThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a new type of controlled cell death. It is distinguished by its reliance on iron and the production of lipid peroxidation. The role of ferroptosis in stroke has attracted a lot of attention recently. The purpose of this review is to clarify the connection between ferroptosis and stroke and to investigate the potential contribution of natural products to the clinical management of stroke and the discovery of novel medications. In this review, we summarize in detail the mechanism of ferroptosis after stroke, especially the relevant targets of ferroptosis after stroke. Furthermore, we summarize the natural products and herbal medicine currently employed in ferroptosis along with their mechanisms of action, highlighting the potential and challenges of clinical translation. We included 55 articles and classified them. After systematic screening, We think that ginkgolide B, kellerin, loureirin C, quercetin, icariside II, salvianolic acid A, berberine, Dl-3-n-butylphthalide is an effective candidate drug for the treatment of stroke.

Indexed as

ferroptosisintracerebral hemorrhageischemic strokenatural productsPhytomedicinestroke

Identifiers

PMID40510422
PMCPMC12159007

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.